The Journal of Immunology, Vol 155, Issue 6 2895-2901, Copyright © 1995 by American Association of Immunologists

ARTICLES

Purification to homogeneity of a novel human B cell differentiation factor

Y De Kuang, M Cidon and L Mayer
Mount Sinai Medical Center, Division of Clinical Immunology, New York, NY 10029, USA.

By immunization with a partially purified form of a novel human B cell differentiation factor, 446-BCDF, we generated a series of mAbs that inhibit the functional activity of this cytokine (induction of Ig secretion by Staphylococcus aureus Cowan I strain organisms-activated B cells). Two mAbs, 929 and 204, were shown to be specific for 446-BCDF in that they failed to inhibit B cell differentiation in response to other known cytokines (IL-2, IL-6) or mitogens (PWM). More importantly, passage of crude 446-BCDF over a mAb 929-Sepharose 4B column resulted in the depletion of 446-BCDF activity, which could be recovered after elution with 0.1 M glycine, pH 2.8. Finally, TCA precipitation of column-eluted fractions was run on SDS-PAGE. Two bands corresponding to the previously described m.w. range of 446-BCDF were detected in the eluate, but not in the effluent column fractions. Furthermore, protein eluted from these bands resolved with nondenaturing gels also demonstrated 446-BCDF activity. Thus, together these data further support the existence of a novel human B cell differentiation factor that has been purified to homogeneity.